• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

1989 年至 2011 年间荷兰头颈部鳞状细胞癌的发病率和生存趋势。

Incidence and survival trends of head and neck squamous cell carcinoma in the Netherlands between 1989 and 2011.

机构信息

Department of Otolaryngology-Head and Neck Surgery, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands.

Department of Otolaryngology-Head and Neck Surgery, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands.

出版信息

Oral Oncol. 2014 Jul;50(7):670-5. doi: 10.1016/j.oraloncology.2014.03.008. Epub 2014 Apr 13.

DOI:10.1016/j.oraloncology.2014.03.008
PMID:24735546
Abstract

BACKGROUND

Incidence and survival trends of head and neck squamous cell carcinoma (HNSCC) are essential knowledge for guiding policy making and research.

METHODS

The total population of the Netherlands was studied covering 1989-2011. Two-and five-year survival and age-standardized incidence rates of HNSCC were assessed in relation to site, gender and age (15 years-of-age categories).

RESULTS

We recorded a statistically significant increase of oral, oropharyngeal and hypopharyngeal carcinoma for males and females of all ages, varying from 0.6% (hypopharynx in males) to 2.7% (oropharynx in females) per year. The incidence of laryngeal carcinoma significantly decreased for males with 2.3% per year; for females the situation was stable. In young adults (below 45 years of age) the incidence figures were different: significant decreasing incidence trends were seen for both genders for carcinomas of the oropharynx, hypopharynx and larynx. Regarding oral carcinoma, no change was observed for the young patient group, but for subsites trends were divergent. Carcinoma of the floor or mouth decreased for both genders, but carcinoma of the tongue rose by a significant 2.8% per year for young males. Five-year survival trends for all ages showed no change for laryngeal carcinoma, a small improvement for oral and hypopharyngeal carcinoma, and a substantial and significant improvement of survival from 36% to 47% survival over the total period for oropharyngeal carcinoma.

CONCLUSION

In the Netherlands for the last two decades, the incidence of oral, oropharyngeal and hypopharyngeal squamous cell carcinoma has increased and survival has improved. The incidence of laryngeal carcinoma has decreased in males, and remained unchanged in females; survival from laryngeal carcinoma has not changed.

摘要

背景

头颈部鳞状细胞癌(HNSCC)的发病率和生存率趋势是指导政策制定和研究的重要知识。

方法

研究了荷兰的总人口,涵盖了 1989 年至 2011 年的数据。评估了 HNSCC 的两年和五年生存率以及年龄标准化发病率,与部位、性别和年龄(15 岁年龄组)有关。

结果

我们记录到男性和女性所有年龄段的口腔、口咽和下咽癌的发病率呈统计学显著增加,每年变化范围为 0.6%(男性下咽)至 2.7%(女性口咽)。男性喉癌的发病率每年显著下降 2.3%;女性情况稳定。在年轻成年人(45 岁以下)中,发病率不同:男性和女性的口咽、下咽和喉癌的发病率呈显著下降趋势。对于口腔癌,年轻患者组没有观察到变化,但亚部位的趋势不同。男性和女性的口腔底部或口腔癌都在减少,但男性舌癌的发病率每年显著增加 2.8%。所有年龄段的五年生存率趋势显示,喉癌没有变化,口腔和下咽癌略有改善,口咽癌的生存率从整个时期的 36%提高到 47%,有实质性和显著改善。

结论

在过去二十年中,荷兰口腔、口咽和下咽鳞状细胞癌的发病率增加,生存率提高。男性喉癌的发病率下降,女性不变;喉癌的生存率没有变化。

相似文献

1
Incidence and survival trends of head and neck squamous cell carcinoma in the Netherlands between 1989 and 2011.1989 年至 2011 年间荷兰头颈部鳞状细胞癌的发病率和生存趋势。
Oral Oncol. 2014 Jul;50(7):670-5. doi: 10.1016/j.oraloncology.2014.03.008. Epub 2014 Apr 13.
2
Oral and oropharyngeal cancer in The Netherlands between 1989 and 2006: Increasing incidence, but not in young adults.1989 年至 2006 年荷兰口腔和口咽癌发病情况:发病率上升,但青年人群除外。
Oral Oncol. 2009 Sep;45(9):e85-9. doi: 10.1016/j.oraloncology.2009.03.010. Epub 2009 May 19.
3
Predicted incidence of oral cavity, oropharyngeal, laryngeal, and hypopharyngeal cancer in Spain and implications for cancer control.西班牙口腔、口咽、喉和下咽癌的预测发病率及其对癌症控制的影响。
Cancer Epidemiol. 2011 Dec;35(6):510-4. doi: 10.1016/j.canep.2011.02.012. Epub 2011 Apr 5.
4
The epidemiology of head and neck squamous cell carcinoma in The Netherlands during the era of HPV-related oropharyngeal squamous cell carcinoma. Is there really evidence for a change?在人乳头瘤病毒(HPV)相关口咽鳞状细胞癌时代,荷兰头颈部鳞状细胞癌的流行病学。真的有变化的证据吗?
Oral Oncol. 2015 Oct;51(10):901-7. doi: 10.1016/j.oraloncology.2015.06.011. Epub 2015 Jul 26.
5
Epidemiological features of cancers of the oral cavity, oropharynx, hypopharynx and larynx cancer in Réunion Island.留尼汪岛口腔癌、口咽癌、下咽癌和喉癌的流行病学特征。
Eur Ann Otorhinolaryngol Head Neck Dis. 2018 Jun;135(3):175-181. doi: 10.1016/j.anorl.2018.01.008. Epub 2018 Apr 16.
6
Trends over three decades of the risk of second primary cancer among patients with head and neck cancer.头颈部癌症患者 30 多年来第二原发癌风险的趋势。
Oral Oncol. 2013 Jan;49(1):9-14. doi: 10.1016/j.oraloncology.2012.06.018. Epub 2012 Jul 26.
7
Prevalence of Synchronous ESCN in Head and Neck Cancer: A Single-Institution Perspective.头颈部癌症中同步 ESCN 的流行率:单机构视角。
Laryngoscope. 2021 Mar;131(3):E807-E814. doi: 10.1002/lary.28821. Epub 2020 Jul 3.
8
To what extent has the last two decades seen significant progress in the management of older patients with head and neck cancer?在过去的二十年中,在老年头颈部癌症患者的管理方面取得了多大程度的显著进展?
Eur J Surg Oncol. 2021 Jun;47(6):1398-1405. doi: 10.1016/j.ejso.2021.01.014. Epub 2021 Jan 29.
9
[Prevalence of human papillomavirus infection in squamous cell carcinoma of the oral cavity, oropharynx and larynx].[口腔、口咽和喉鳞状细胞癌中人乳头瘤病毒感染的患病率]
Cir Cir. 2016 Sep-Oct;84(5):363-8. doi: 10.1016/j.circir.2016.01.006. Epub 2016 Mar 28.
10
Head and neck squamous cell carcinoma in people living with HIV in France.法国 HIV 感染者的头颈部鳞状细胞癌。
Med Mal Infect. 2018 Dec;48(8):503-508. doi: 10.1016/j.medmal.2018.05.002. Epub 2018 Jun 7.

引用本文的文献

1
The Role of Klotho in Oral and Maxillofacial Diseases: Mechanisms and Research Progress.α-klotho在口腔颌面部疾病中的作用:机制与研究进展
Biomolecules. 2025 Apr 27;15(5):624. doi: 10.3390/biom15050624.
2
A Comprehensive Review on LncRNAs/miRNAs-DNMT1 Axis in Human Cancer: Mechanistic and Clinical Application.人类癌症中长链非编码RNA/微小RNA- DNA甲基转移酶1轴的综合综述:作用机制与临床应用
J Cell Mol Med. 2025 May;29(10):e70604. doi: 10.1111/jcmm.70604.
3
Nasopharyngeal, tongue and laryngeal cancer in Southern Ethiopia: a seven-year retrospective cross-sectional review.
埃塞俄比亚南部的鼻咽癌、舌癌和喉癌:一项为期七年的回顾性横断面研究。
Ecancermedicalscience. 2024 Oct 8;18:1784. doi: 10.3332/ecancer.2024.1784. eCollection 2024.
4
Non-smoking and Non-drinking Oral Cancer Patients Are at Higher Risk of Second Primary Tumours.不吸烟不饮酒的口腔癌患者发生第二原发性肿瘤的风险更高。
Oral Dis. 2025 Jul;31(7):2129-2138. doi: 10.1111/odi.15235. Epub 2024 Dec 30.
5
Triple Positive Oral Squamous Cell Carcinoma Patients Predict Poor Survival Outcomes: Multiple Factor Positivity Warrants the Need for Modified Treatment Approaches.三阳性口腔鳞状细胞癌患者预示着不良生存结果:多种因素呈阳性表明需要改进治疗方法。
J Maxillofac Oral Surg. 2024 Aug;23(4):923-934. doi: 10.1007/s12663-024-02186-5. Epub 2024 Apr 29.
6
Survival in oral and pharyngeal cancers is catching up with laryngeal cancer in the NORDIC countries through a half century.经过半个世纪的发展,北欧国家口咽癌的生存率已经赶上了喉癌。
Cancer Med. 2024 Jan;13(1):e6867. doi: 10.1002/cam4.6867. Epub 2024 Jan 2.
7
Oral squamous cell carcinoma - do we always need elective neck dissection? evaluation of clinicopathological factors of greatest prognostic significance: a cross-sectional observational study.口腔鳞状细胞癌——我们总是需要选择性颈清扫术吗?对具有最大预后意义的临床病理因素的评估:一项横断面观察性研究。
Front Oncol. 2023 Sep 14;13:1203439. doi: 10.3389/fonc.2023.1203439. eCollection 2023.
8
Mutant HRas Signaling and Rationale for Use of Farnesyltransferase Inhibitors in Head and Neck Squamous Cell Carcinoma.突变 HRas 信号传导和法尼基转移酶抑制剂在头颈部鳞状细胞癌中应用的原理。
Target Oncol. 2023 Sep;18(5):643-655. doi: 10.1007/s11523-023-00993-3. Epub 2023 Sep 4.
9
Predictive value of tumor budding in head and neck squamous cell carcinoma: an update.肿瘤芽在头颈部鳞状细胞癌中的预测价值:更新。
Virchows Arch. 2023 Oct;483(4):441-449. doi: 10.1007/s00428-023-03630-6. Epub 2023 Aug 29.
10
Ultrasound and Microbubbles Mediated Bleomycin Delivery in Feline Oral Squamous Cell Carcinoma-An In Vivo Veterinary Study.超声与微泡介导博来霉素在猫口腔鳞状细胞癌中的递送——一项体内兽医研究
Pharmaceutics. 2023 Apr 6;15(4):1166. doi: 10.3390/pharmaceutics15041166.